Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 19)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
6-Feb-10 Standard & Poor's Quantitative Report N/A Ardea Biosciences Inc 6 $25 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ARDEA BIOSCIENCES INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for RDEA: the economy's impact on RDEA's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
27-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD RDEA: Positive Update after Meeting with Management 5 $10 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
11-Jan-10 Brean Murray & Co., Inc. Eric M. Beder RDEA: Expecting Positive Phase 2b Data This Quarter to Define Phase 3 Program 4 $10 View Abstract
11-Jan-10 Brean Murray & Co., Inc. Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Bret Jones Morning Insight (RICK, FOSL, HBI, MDRX, RDEA, Water Works Weekly, Clean Energy Weekly, Utilities Weekly) 14 $50 View Abstract
7-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD RDEA: Ardea Annouces Positive Results from Phase 2a and Phase 1 Drug-Drug Interaction Trials 4 $10 View Abstract
Next 9

Brokerage Reports (Showing 1 to 4 of 4)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
27-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD RDEA: Positive Update after Meeting with Management 5 $10 View Abstract
11-Jan-10 Brean Murray & Co., Inc. Eric M. Beder RDEA: Expecting Positive Phase 2b Data This Quarter to Define Phase 3 Program 4 $10 View Abstract
11-Jan-10 Brean Murray & Co., Inc. Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Bret Jones Morning Insight (RICK, FOSL, HBI, MDRX, RDEA, Water Works Weekly, Clean Energy Weekly, Utilities Weekly) 14 $50 View Abstract
7-Jan-10 Brean Murray & Co., Inc. Jonathan M. Aschoff PhD RDEA: Ardea Annouces Positive Results from Phase 2a and Phase 1 Drug-Drug Interaction Trials 4 $10 View Abstract

Independent Reports (Showing 1 to 10 of 15)

Release
Date Contributor Author Title Pages Price More Info
6-Feb-10 Standard & Poor's Quantitative Report N/A Ardea Biosciences Inc 6 $25 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ARDEA BIOSCIENCES INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for RDEA: the economy's impact on RDEA's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
6-Jan-10 Global Markets Direct Global Markets Direct Ardea Biosciences, Inc. Financial and Strategic Analysis Review 18 $300 View Abstract
4-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
27-Dec-09 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ARDEA BIOSCIENCES INC 5 $25 View Abstract
30-Mar-09 PriceTarget Research, Inc. N/A Ardea Biosciences has a current Overall Rating of C (Neutral). 7 $25 View Abstract
Next 5

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.